Riverbridge Partners LLC Reduces Stake in Heska Corp (NASDAQ:HSKA)
Riverbridge Partners LLC lowered its holdings in Heska Corp (NASDAQ:HSKA) by 0.9% during the fourth quarter, HoldingsChannel reports. The fund owned 289,806 shares of the medical research company’s stock after selling 2,660 shares during the period. Riverbridge Partners LLC’s holdings in Heska were worth $27,804,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of HSKA. SG Capital Management LLC purchased a new stake in shares of Heska during the 3rd quarter worth approximately $20,182,000. Russell Investments Group Ltd. acquired a new stake in shares of Heska during the third quarter worth about $4,588,000. Nine Ten Capital Management LLC purchased a new stake in shares of Heska in the 2nd quarter valued at about $3,728,000. Johanson Financial Advisors Inc. purchased a new stake in shares of Heska in the 4th quarter valued at about $415,000. Finally, Nuveen Asset Management LLC acquired a new stake in shares of Heska in the 2nd quarter valued at about $3,221,000. 97.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:HSKA traded down $0.72 on Tuesday, reaching $96.73. The company’s stock had a trading volume of 35,925 shares, compared to its average volume of 51,422. The stock’s 50-day moving average is $95.59 and its two-hundred day moving average is $82.05. Heska Corp has a 52-week low of $62.47 and a 52-week high of $102.09. The company has a debt-to-equity ratio of 0.31, a current ratio of 8.52 and a quick ratio of 6.80. The stock has a market capitalization of $753.40 million, a P/E ratio of 68.12 and a beta of 1.10.
A number of research analysts recently issued reports on HSKA shares. ValuEngine downgraded Heska from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 3rd. Zacks Investment Research cut Heska from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Piper Jaffray Companies started coverage on Heska in a report on Wednesday, September 18th. They issued a “neutral” rating and a $68.00 price objective for the company. Raymond James downgraded Heska from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. They noted that the move was a valuation call. Finally, Canaccord Genuity restated a “buy” rating and set a $105.00 target price (up from $75.00) on shares of Heska in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $85.75.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Recommended Story: Trade War
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.